Sort   by:  
 Page size 
UnknownCalcium sensor kinase activates potassium uptake systems in gland cells of Venus flytraps.
Not available
S-EPMC4466697 | biostudies-literature
UnknownSmall molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
Not available
S-EPMC2847740 | biostudies-literature
ProteomicsThe proto-oncogene TCL1A deregulates mitotic checkpoint transition and genomic stability in CLL
Upregulation of the proto-oncogene TCL1A is causally implicated in various B- and T-cell malignancies. High-level TCL1A correlates with aggressive disease features and inferior clinical outcomes. However, molecular and cell-biological consequences of TCL1A dysregulation are not fully elucidated. Her...
ORGANISM(S): Homo sapiens (Human) 
2022-11-14 | PXD030776 | Pride
Tcl1a Leukemia Cdc20 Mitotic checkpoint Aneuploidy 
ProteomicsThe proto-oncogene TCL1A deregulates mitotic checkpoint transition and genomic stability in CLL
Upregulation of the proto-oncogene TCL1A is causally implicated in various B- and T-cell malignancies. High-level TCL1A correlates with aggressive disease features and inferior clinical outcomes. However, molecular and cell-biological consequences of TCL1A dysregulation are not fully elucidated. Her...
ORGANISM(S): Homo sapiens (Human) 
2022-11-14 | PXD030773 | Pride
Tcl1a Leukemia Cdc20 Mitotic checkpoint Aneuploidy 
UnknownGeneral condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia.
Not available
S-EPMC10316257 | biostudies-literature
TranscriptomicsWhole-exome sequencing identifies mutations of BCOR in acute myeloid leukemia with normal karyotype
Among acute myeloid leukemias (AML) with normal karyotype (CN-AML), NPM1 and CEBPA mutations define WHO provisional entities accounting for ~60% of cases, but the remaining ~40% remains poorly characterized. By whole exome-sequencing (WES) of one CN-AML patient lacking mutations in NPM1, CEBPA, FLT3...
ORGANISM(S): Homo sapiens 
2011-12-16 | E-GEOD-30442 | biostudies-arrayexpress
UnknownMinimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.
Not available
S-EPMC8678026 | biostudies-literature
UnknownTranscriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Not available
S-EPMC10113251 | biostudies-literature
TranscriptomicsRNA-seq of Chronic Lymphocytic Leukemia patients with and without t(14;19) samples, and normal mature B cells
Characterize the transcriptomes of CLL with and without t(14;19)
ORGANISM(S): Homo sapiens 
2026-07-14 | E-MTAB-15004 | biostudies-arrayexpress
UnknownVenetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.
Not available
S-EPMC11551846 | biostudies-literature
Sort   by:  
 Page size